Altimmune (ALT) Change in Receivables (2010 - 2026)
Altimmune (ALT) reported Change in Receivables of $446000.0 for Q1 2026, up 1305.41% year-over-year from $31734.6 in Q1 2025, and up 19.25% quarter-over-quarter from $374000.0 in Q4 2025.
Altimmune (ALT) Change in Receivables (2010 - 2026) Analysis & Trends
Altimmune (ALT) has 17 years of Change in Receivables data on file, last reported at $446000.0 in Q1 2026.
- Change in Receivables for Q1 2026 came in at $446000.0, up 1305.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (up 479.0% YoY), and the FY2025 annual result was $675000.0, up 219.05% from the prior year.
- Change in Receivables rose to $446000.0 in Q1 2026 per ALT's latest filing, from $374000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $741000.0 in Q3 2023 and troughed at -$804000.0 in Q1 2024.
- A 5-year average of $72705.9 and a median of $80000.0 in 2023 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2023 and 2025: Change in Receivables plunged 4000.0% in 2023, then soared 13000.0% in 2025.
- A 5-year view of Change in Receivables shows it stood at -$460000.0 in 2022, then soared by 150.87% to $234000.0 in 2023, then tumbled by 50.43% to $116000.0 in 2024, then soared by 222.41% to $374000.0 in 2025, then increased by 19.25% to $446000.0 in 2026.
- Business Quant data shows ALT's Change in Receivables at $446000.0 in Q1 2026, $374000.0 in Q4 2025, and $524000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | 446,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 446,000.00 |
| Mar 31, 2026 | 446,000.00 |
| Dec 31, 2025 | 374,000.00 |
| Dec 31, 2025 | 374,000.00 |
| Sep 30, 2025 | 524,000.00 |
| Sep 30, 2025 | 524,000.00 |
| Jun 30, 2025 | -186,000.00 |
| Jun 30, 2025 | -186,000.00 |
| Mar 31, 2025 | -37,000.00 |
| Mar 31, 2025 | -37,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 117,000.00 |
| Jun 30, 2024 | 117,000.00 |
| Mar 31, 2024 | -804,000.00 |
| Mar 31, 2024 | -804,000.00 |
| Dec 31, 2023 | 234,000.00 |
| Dec 31, 2023 | 234,000.00 |